Latest news with #ACADIAPharmaceuticals
Business Insider
4 days ago
- Business
- Business Insider
ACADIA Pharmaceuticals (ACAD) Gets a Hold from Bank of America Securities
In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $23.00. The company's shares closed yesterday at $21.77. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Ahmad is an analyst with an average return of -1.3% and a 49.49% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Incyte, Sarepta Therapeutics, and PTC Therapeutics. In addition to Bank of America Securities, ACADIA Pharmaceuticals also received a Hold from Morgan Stanley's Sean Laaman in a report issued on May 20. However, on the same day, Deutsche Bank upgraded ACADIA Pharmaceuticals (NASDAQ: ACAD) to a Buy. ACAD market cap is currently $3.59B and has a P/E ratio of 16.00. Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACAD in relation to earlier this year. Most recently, in March 2025, ELIZABETH A. GAROFALO, a Director at ACAD sold 4,919.00 shares for a total of $89,673.37.
Business Insider
15-05-2025
- Business
- Business Insider
Bank of America Securities Reaffirms Their Hold Rating on ACADIA Pharmaceuticals (ACAD)
Bank of America Securities analyst Tazeen Ahmad reiterated a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report) yesterday and set a price target of $18.00. The company's shares closed yesterday at $17.16. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Ahmad covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, PTC Therapeutics, and Alnylam Pharma. According to TipRanks, Ahmad has an average return of -5.3% and a 43.00% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $25.44 average price target, which is a 48.25% upside from current levels. In a report released on May 8, Stifel Nicolaus also maintained a Hold rating on the stock with a $18.00 price target. Based on ACADIA Pharmaceuticals' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $244.32 million and a net profit of $18.99 million. In comparison, last year the company earned a revenue of $205.83 million and had a net profit of $16.56 million Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACAD in relation to earlier this year. Most recently, in March 2025, ELIZABETH A. GAROFALO, a Director at ACAD sold 4,919.00 shares for a total of $89,673.37.
